

Date: 14/08/2019

FREEDOM OF INFORMATION REQUEST FOI/014938 - Breast cancer

We are currently researching the NICE Guidelines and its impact on procurement, and access to the market.

We are looking specifically at diagnostics - NICE Guidance - DG34 - tumour profiling for breast cancer, as a recent example.

We would like to understand any procurement plans you have in place as a result of this? Including dates, procurement route (open, restricted), regime (whether light touch regime, standard OJEU), likely weightings (quality vs price), or via NHS Supply Chain or other framework provider?

The Trust is 'Fully Compliant' with the guidance as we do use Oncotype DX Breast Recurrence Score (Rec 1.1), the Trust is only aware of one supplier.